User menu

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

Bibliographic reference De Clercq, Erik. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. In: Expert Opinion on Pharmacotherapy, Vol. 10, no. 17, p. 2935-2937 (2009)
Permanent URL http://hdl.handle.net/2078.1/34851
  1. Lennox Jeffrey L, DeJesus Edwin, Lazzarin Adriano, Pollard Richard B, Madruga Jose Valdez Ramalho, Berger Daniel S, Zhao Jing, Xu Xia, Williams-Diaz Angela, Rodgers Anthony J, Barnard Richard JO, Miller Michael D, DiNubile Mark J, Nguyen Bach-Yen, Leavitt Randi, Sklar Peter, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, 10.1016/s0140-6736(09)60918-1
  2. Hazuda D. J., Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells, 10.1126/science.287.5453.646
  3. Hazuda D. J., Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques, 10.1126/science.1098632
  4. Grinsztejn Beatriz, Nguyen Bach-Yen, Katlama Christine, Gatell Jose M, Lazzarin Adriano, Vittecoq Daniel, Gonzalez Charles J, Chen Joshua, Harvey Charlotte M, Isaacs Robin D, Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, 10.1016/s0140-6736(07)60597-2
  5. Steigbigel Roy T., Cooper David A., Kumar Princy N., Eron Joseph E., Schechter Mauro, Markowitz Martin, Loutfy Mona R., Lennox Jeffrey L., Gatell Jose M., Rockstroh Jurgen K., Katlama Christine, Yeni Patrick, Lazzarin Adriano, Clotet Bonaventura, Zhao Jing, Chen Joshua, Ryan Desmond M., Rhodes Rand R., Killar John A., Gilde Lucinda R., Strohmaier Kim M., Meibohm Anne R., Miller Michael D., Hazuda Daria J., Nessly Michael L., DiNubile Mark J., Isaacs Robin D., Nguyen Bach-Yen, Teppler Hedy, Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection, 10.1056/nejmoa0708975
  6. Cooper David A., Steigbigel Roy T., Gatell Jose M., Rockstroh Jurgen K., Katlama Christine, Yeni Patrick, Lazzarin Adriano, Clotet Bonaventura, Kumar Princy N., Eron Joseph E., Schechter Mauro, Markowitz Martin, Loutfy Mona R., Lennox Jeffrey L., Zhao Jing, Chen Joshua, Ryan Desmond M., Rhodes Rand R., Killar John A., Gilde Lucinda R., Strohmaier Kim M., Meibohm Anne R., Miller Michael D., Hazuda Daria J., Nessly Michael L., DiNubile Mark J., Isaacs Robin D., Teppler Hedy, Nguyen Bach-Yen, Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, 10.1056/nejmoa0708978
  7. De Clercq Erik, Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV, 10.1016/j.ijantimicag.2008.10.010
  8. De Clercq Erik, The history of antiretrovirals: key discoveries over the past 25 years, 10.1002/rmv.624
  9. De Clercq Erik, From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™, 10.2217/17460794.1.6.709
  10. De Clercq E, Med Res Rev (2009)